Date:	8/1/2024
Your Name:	Katie Scandrett
Manuscript Title:	Rapid tests to inform triage and antibiotic prescribing decisions for adults presenting with suspected acute respiratory infection: A rapid evidence synthesis of clinical effectiveness and cost-utility studies
Manuscript Number (if known):	NIHR159946

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)		ications/Comments (e.g., if onts were made to you or to your tion)
		Time frame: Since the initial planning	g of the	work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	This work was funded by the NIHR Evidence Synthesis Programme, project number NIHR159946 Supported by the NIHR Birmingham Biomed Research Centre at the University Hospitals Birmingham NHS Foundation Trust and the University of Birmingham.	ical	Funding was paid to the University of and the University of Birmingham Funding was paid to the University I Birmingham NHS Foundation Trust I University of Birmingham.
		Time frame: past 36 mont	hs	
2	Grants or contracts from any entity (if not indicated in item #1 above).	⊠ None		

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
3	Royalties or licenses	None None □	
4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations , speakers bureaus, manuscript writing or educational events	None None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	

			es with whom you have p or indicate none (add l)	ications/Comments (e.g., if ents were made to you or to your tion)
1 0	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	⊠ None		
1	Stock or stock options	None None		
1 2	Receipt of equipment, materials, drugs, medical writing, gifts or other services	⊠ None		
1 3	Other financial or non-financial interests	⊠ None		
Please place an "X" next to the following statement to indicate your agreement: I certify that I have answered every question and have not altered the wording of any of the questions on this form.				

Date:	_7/17/2023
Your Name:	Jill Colquitt
Manuscript Title:	Rapid tests to inform triage and antibiotic prescribing decisions for adults presenting with suspected acute respiratory infection: A rapid evidence synthesis of clinical effectiveness and cost-utility studies
Manuscript Number (if known):	NIHR159946

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	Time frame: Since the initial plannin	g of the work
1 All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. 2 Grants or contracts from any entity (if not indicated in item #1 above).	This work was funded by the NIHR Evidence Synthesis Programme, project number NIHR159946 Time frame: past 36 mon	Funding was paid to the University of and the University of Birmingham Click the tab key to add additional rows.
3 Royalties or licenses4 Consulting fees	None None None	

			tities with whom you have ship or indicate none (add led)	ications/Comments (e.g., if ents were made to you or to your tion)
5	Payment or honoraria for lectures, presentations , speakers bureaus, manuscript writing or educational events	⊠ None		
6	Payment for expert testimony	⊠ None		
7	Support for attending meetings and/or travel	⊠ None		
8	Patents planned, issued or pending	⊠ None		
9	Participation on a Data Safety Monitoring Board or Advisory Board	⊠ None		
1 0	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	⊠ None		

		this r	e all entities with whom you have elationship or indicate none (add as needed)		ications/Comments (e.g., if ents were made to you or to your tion)	
1	Stock or stock options		None			
1 2	Receipt of equipment, materials, drugs, medical writing, gifts or other services		None			
1 3	Other financial or non-financial interests		None			
Please place an "X" next to the following statement to indicate your agreement: I certify that I have answered every question and have not altered the wording of any of the questions on this form.						

Date:	7/29/2023
Your Name:	Rachel Court
Manuscript Title:	Rapid tests to inform triage and antibiotic prescribing decisions for adults presenting with suspected acute respiratory infection: A rapid evidence synthesis of clinical effectiveness and cost-utility studies
Manuscript Number (if known):	NIHR159946

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	Time frame: Since the initial planni	ng of the work
1 All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	This work was funded by the NIHR Evidence Synthesis Programme, project number NIHR159946	
	Time frame: past 36 mor	nths
 Grants or contracts from any entity (if not indicated in item #1 above). Royalties or licenses 	None None None	
4 Consulting fees	None Non	
5 Payment or	⊠ None	
honoraria for lectures, presentations , speakers bureaus, manuscript writing or		

		Name all entities with whom you have this relationship or indicate none (add rows as needed)		fications/Comments (e.g., if ents were made to you or to your tion)
	educational events		·	
6	Payment for expert testimony	None		
7	Support for attending meetings and/or travel	None None		
8	Patents planned, issued or pending	⊠ None		
9	Participation on a Data Safety Monitoring Board or Advisory Board	None		
1 0	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None		
1	Stock or stock options	None		
1 2	Receipt of equipment, materials, drugs, medical writing, gifts	None		

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	or other services		
1 3	Other financial or non-financial interests	None	
Ple 🖂	•	" next to the following statement to indicat ave answered every question and have not al-	•

Date:	7/20/2023	
Your Name:	Fiona Whiter	
Manuscript Title:	Rapid tests to inform triage and antibiotic prescribing decisions for adults presenting with suspected acute respiratory infection: A rapid evidence synthesis of clinical effectiveness and cost-utility studies	
Manuscript Number (if known):	NIHR159946	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial plann	ing of the work
1	All support for the present manuscript (e.g., funding,	□ None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)		ications/Comments (e.g., if ents were made to you or to your tion)	
	provision of study materials, medical	This work was funded by the NIHR Evidence Synthesis Programme, project number NIHR159946		Funding was paid to the University and the University of Birmingham	of Warwick
	writing, article processing charges, etc.) No time limit for this item.			Click the tab key to add additional rows.	
		Time frame: past 36 mont	:hs		
2	Grants or contracts	☑ None			
	from any entity (if not indicated in				
	item #1 above).				
3	Royalties or licenses	⊠ None			
4	Consulting fees	⊠ None			
5	Payment or honoraria for	⊠ None			
	lectures,				
	presentations , speakers				
	bureaus, manuscript writing or educational events				
6	Payment for expert	⊠ None			
	testimony				

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	ications/Comments (e.g., if ents were made to you or to your tion)
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
1 0	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
1	Stock or stock options	None	
1 2	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
1 3	Other financial or non-financial interests	None None	

	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
_	Please place an "X" next to the following statement to indicate your agreement:			
I certify that I have answered every question and have not altered the wording of any of the questions on this form.				

Date:	7/31/2023
Your Name:	Bethany Shinkins
Manuscript Title:	Rapid tests to inform triage and antibiotic prescribing decisions for adults presenting with suspected acute respiratory infection: A rapid evidence synthesis of clinical effectiveness and cost-utility studies
Manuscript Number (if known):	NIHR159946

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	-	cations/Comments (e.g., if nts were made to you or to your ion)
		Time frame: Since the initial plannir	g of the v	vork
1	All support for the present	□ None		
	manuscript (e.g., funding, provision of study	This work was funded by the NIHR Evidence Synthesis Programme, project number NIHR159946	2	Funding was paid to the University and the University of Birmingham
	materials, medical writing, article processing charges, etc.) No time limit for this item.			Click the tab key to add additional rows.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
		Time frame: past 36 mont	hs		
cont from entit		None I am an unfunded co-applicant on an NIHR Application Accelerator Award (platform str in areas considered strategic priorities) – led Phillip Pallman at Cardiff University and En Carrol at the University of Liverpool. The proposed platform trial will focus on evaluat diagnostic technologies for those presenting suspected bacterial infection to emergency continued to the proposed platform trial will focus on evaluate the proposed platform trial will be proposed platform tria	HTA udies by itan ing with	No funding has been received by the of Warwick for this work – we expensively be costed into the full HTA appropriate which will be submitted at the end of November.	
3 Roya licen	alties or nses	None None			
4 Cons fees	sulting	None None			
	ment or	⊠ None			
lectu preso , spe bure man writi	oraria for ures, sentations eakers eaus, nuscript cational nts				
1 1	ment for	⊠ None			
expe testi	imony				
	port for	⊠ None			
mee	ending etings /or travel				

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
1 0	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	⊠ None	
1 1	Stock or stock options	None	
1 2	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
1 3	Other financial or non-financial interests	⊠ None	
Ple	Please place an "X" next to the following statement to indicate your agreement: I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date:	8/1/2024
Your Name:	Yemisi Takwoingi
Manuscript Title:	Rapid tests to inform triage and antibiotic prescribing decisions for adults presenting with suspected acute respiratory infection: A rapid evidence synthesis of clinical effectiveness and cost-utility studies
Manuscript Number (if known):	NIHR159946

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)		ications/Comments (e.g., if ents were made to you or to your tion)
		Time frame: Since the initial plannin	g of the	work
1	All support for the present	□ None		
	manuscript (e.g., funding, provision of study	This work was funded by the NIHR Evidence Synthesis Programme, project number NIHR159946		Funding was paid to the University of and the University of Birmingham
	materials, medical writing, article processing charges, etc.) No time limit for this item.	Supported by the NIHR Birmingham Biomedical Research Centre at the University Hospitals Birmingham NHS Foundation Trust and the University of Birmingham.		Funding was paid to the University I Birmingham NHS Foundation Trust University of Birmingham
		Time frame: past 36 mon	ths	
2	Grants or contracts from any entity (if not indicated in item #1 above).	None		

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
3	Royalties or licenses	None None	
4	Consulting fees	None None □	
5	Payment or honoraria for lectures, presentations , speakers bureaus, manuscript writing or educational events	None ■	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1 0	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	⊠ None	
1	Stock or stock options	None	
1 2	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X None	
1 3	Other financial or non-financial interests	⊠ None	
	-	'next to the following statement to indicate ave answered every question and have not alt	

Date:	7/26/2023
Your Name:	Emma Loveman
Manuscript Title:	Rapid tests to inform triage and antibiotic prescribing decisions for adults presenting with suspected acute respiratory infection: A rapid evidence synthesis of clinical effectiveness and cost-utility studies
Manuscript Number (if known):	NIHR159946

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	Time frame: Since the initial plannin	g of the work
All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	This work was funded by the NIHR Evidence Synthesis Programme, project number NIHR159946	and the University of Birmingham Click the tab key to add additional rows.
	Time frame: past 36 mon	ths
Grants or contracts from any entity (if not indicated in item #1 above).	None None	
3 Royalties or licenses	⊠ None	
licenses		
4 Consulting fees	⊠ None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
5	Payment or honoraria for lectures, presentations , speakers bureaus, manuscript writing or educational events	None None	
6	Payment for expert testimony	None None	
7	Support for attending meetings and/or travel	None None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
1 0	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	

		this r	e all entities with whom you have elationship or indicate none (add as needed)		cations/Comments (e.g., if nts were made to you or to your tion)	
1	Stock or stock		None			
1	options					
1 2	Receipt of equipment,		None			
	materials, drugs,					
	medical					
	writing, gifts or other					
	services					
1	Other		None			
3	financial or non-financial					
	interests					
Ple	ase place an "X'	" next 1	to the following statement to indicate	your ag	reement:	
\boxtimes	I certify that I h this form.	ave ans	swered every question and have not alte	red the v	vording of any of the questions on	

Date:	7/30/2021
Your Name:	Dan Todkill
Manuscript Title:	Rapid tests to inform triage and antibiotic prescribing decisions for adults presenting with suspected acute respiratory infection: A rapid evidence synthesis of clinical effectiveness and cost-utility studies
Manuscript Number (if known):	NIHR159946

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for	Time frame: Since the initial planni	ing of the work
	the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit	This work was funded by the NIHR Evidence Synthesis Programme, project number NIHR159946	Funding was paid to the University and the University of Birmingham Click the tab key to add additional rows.
	for this item.	-	
		Time frame: past 36 mo	nths
2	Grants or contracts from any entity (if not indicated in item #1 above).	None None	
3	Royalties or licenses	None Non	
4	Consulting fees	None Non	
5	Payment or honoraria for lectures, presentations , speakers bureaus,	None None	
	presentations , speakers		

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	educational events		
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None None	
1 0	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None None	
1	Stock or stock options	None None	
1 2	Receipt of equipment, materials, drugs, medical writing, gifts	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	or other services		
1 3	Other financial or non-financial interests	None	
Ple 🖂	•	" next to the following statement to indicanave answered every question and have not a	te your agreement: Itered the wording of any of the questions on

Date:	7/19/2023
Your Name:	Paramjit Gill
Manuscript Title:	Rapid tests to inform triage and antibiotic prescribing decisions for adults presenting with suspected acute respiratory infection: A rapid evidence synthesis of clinical effectiveness and cost-utility studies
Manuscript Number (if known):	NIHR159946

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		this relationship or indicate none (add p	specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning o	of the work
1	All support for the present manuscript (e.g., funding,	□ None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
	provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	This work was funded by the NIHR Evidence Synthesis Programme, project number NIHR159946 Co-Chair NIHR RIGHT Panel	Payment to University of Warwick Click the tab key to add additional rows.	Warw
		Time frame: past 36 mon	ths	
2	Grants or contracts	□ None		
	from any	NIHR Senior Investigator	Payment to University of Warwick	
	entity (if not indicated in			
	item #1 above).			
3	Royalties or licenses	⊠ None		
	licenses			
4	Consulting	⊠ None		
	fees			
5	Payment or	⊠ None		
	honoraria for lectures,			
	presentations			
	, speakers bureaus,			
	manuscript			
	writing or educational			
	events	57 N		
6	Payment for expert	⊠ None		
	testimony			

		Name all entities with whom you have this relationship or indicate none (add rows as needed)		cations/Comments (e.g., if nts were made to you or to your tion)
7	Support for attending meetings and/or travel	None None		
8	Patents planned, issued or pending	None		
9	Participation on a Data Safety Monitoring Board or Advisory Board	OPTIMAL Steering Group Enhanced Safety Group, PANORAMIC	Trial	No payment Funding to University of Warwick
1 0	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None		
1 1	Stock or stock options	None		
1 2	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None		
1 3	Other financial or non-financial interests	Nihr Work and Health Development Av	vards	No payment

	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
•	" next to the following statement to indicate	•
\boxtimes this form.	nave answered every question and have not alto	ered the wording of any of the questions on

Date:	8/14/2024
Your Name:	Daniel Lasserson
Manuscript Title:	Rapid tests to inform triage and antibiotic prescribing decisions for adults presenting with suspected acute respiratory infection: A rapid evidence synthesis of clinical effectiveness and cost-utility studies
Manuscript Number (if known):	NIHR159946

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	-	cations/Comments (e.g., if nts were made to you or to your ion)
		Time frame: Since the initial plannir	g of the v	vork
1	All support for the present	□ None		
	manuscript (e.g., funding, provision of study	This work was funded by the NIHR Evidence Synthesis Programme, project number NIHR159946	2	Funding was paid to the University and the University of Birmingham
	materials, medical writing, article processing charges, etc.) No time limit for this item.			Click the tab key to add additional rows.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: past 36 mon	aths
2	Grants or contracts from any entity (if not indicated in item #1 above).	NHS England West Midlands NIHR Funding: Health Technology Assessive Programme (NIHR 135832), Policy Resear Programme (NIHR 202691, NIHR 200718) MedTech and IVD Cooperative Programme (Theme Lead, Community Healthcare), Appresearch Collaboration Programme, (Theme Lead, West Midlands), Biomedical Research Centre programme (Sub theme co-lead, Oxibutterfly Net Inc Vifor Pharma Ltd Unfunded co-applicants on an NIHR HTA Application Accelerator Award (platform studies in areas considered strategic prioriticled by Dr Phillip Pallman at Cardiff Universitative and Professor Enitan Carrol at the Universitative Incurrence on evaluating diagnostic technologies those presenting with suspected bacterial infection to emergency care. Undertook a service evaluation (not funded by the companies) of Abbott and Afinion point of tests and other point of care test research stranded by the Health Foundation or through core NIHR infrastructure awards.	ch), e plied ne ch ford). Contract with Oxford University He NHS Foundation Trust for institutic payments (none made to date) Paid to University of Birmingham les) — esity ty of care udies
3	Royalties or licenses	None None □	
4	Consulting fees	None None	
5	Payment or honoraria for	⊠ None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
6	lectures, presentations , speakers bureaus, manuscript writing or educational events Payment for	None		
7	expert testimony			
,	Support for attending meetings and/or travel	None		
8	Patents planned, issued or pending	None		
9	Participation on a Data Safety Monitoring Board or Advisory Board	Chair of Study Steering Group Aster AKI (National Study Steering Study Steering Group Aster AKI (National Study Steerin	THR No payments	
1 0	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	President of UK Hospital at Home Society	No Payments made.	
1	Stock or stock options	None		

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1 2	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
1 3	Other financial or non-financial interests	None HTA Clinical Evaluation and Trials Committee 20162021	
Ple	-	" next to the following statement to indicate ave answered every question and have not alto	

8/1/2023
Lena Alkhudairy
Rapid tests to inform triage and antibiotic prescribing decisions for adults presenting with suspected acute respiratory infection: A rapid evidence synthesis of clinical effectiveness and cost-utility studies
NIHR159946

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of	□ None This work was funded by the NIHR Evidence Synthesis Programme, project number NIHR159946	Funding was paid to the University of and the University of Birmingham
	study materials, medical writing, article processing charges, etc.) No time limit for this item.		Click the tab key to add additional rows.
		Time frame: past 36 month	hs
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None None	
4	Consulting fees	□ None	
5	Payment or honoraria for lectures, presentations , speakers bureaus, manuscript writing or educational events	None None □	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
1 0	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None None	
1 1	Stock or stock options	None	
1 2	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1 3	Other financial or non-financial interests	None None	
Ple	•	" next to the following statement to indicate ave answered every question and have not alte	

Date:	8/1/2024
Your Name:	Professor Amy grove
Manuscript Title:	Rapid tests to inform triage and antibiotic prescribing decisions for adults presenting with suspected acute respiratory infection: A rapid evidence synthesis of clinical effectiveness and cost-utility studies
Manuscript Number (if known):	NIHR159946

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial plannir	ng of the work
1	All support for the present	□ None	
	manuscript (e.g., funding, provision of	This work was funded by the NIHR Evidence Synthesis Programme, project number NIHR159946	Funding was paid to the University and the University of Birmingham
	study materials,		Click the tab key to add additional rows.

		Name all entities with who this relationship or indicat rows as needed)	te none (add p	pecifications/Comments (e.g., if ayments were made to you or to your nstitution)
	medical writing, article processing charges, etc.) No time limit for this item.			
		Time fra	ame: past 36 months	
2	Grants or contracts from any entity (if not indicated in item #1 above).	⊠ None		
3	Royalties or licenses	⊠ None		
4	Consulting fees	⊠ None		
5	Payment or honoraria for lectures, presentations , speakers bureaus, manuscript writing or educational events	⊠ None		
6	Payment for expert testimony	⊠ None		

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None None	
1 0	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
1 1	Stock or stock options	None	
1 2	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
1 3	Other financial or non-financial interests	None HTA Commissioning Committee 2023-20	024.

	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Please place an "X"	" next to the following statement to indicate	your agreement:
I certify that I have answered every question and have not altered the wording of any of the questions on $[\boxtimes]$ this form.		

Date:	7/27/2021		
Your Name:	Yen-Fu Chen		
Manuscript Title:	Rapid tests to inform triage and antibiotic prescribing decisions for adults presenting with suspected acute respiratory infection: A rapid evidence synthesis of clinical effectiveness and cost-utility studies		
Manuscript Number (if known):	NIHR159946		

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	-	cations/Comments (e.g., if nts were made to you or to your tion)
		Time frame: Since the initial plannin	g of the	work
1	All support for the present	□ None		
manuscript (e.g., funding, provision of		This work was funded by the NIHR Evidence Synthesis Programme, project number NIHR159946	!	Funding was paid to the University and the University of Birmingham
	study materials,			Click the tab key to add additional rows.
	medical writing, article processing charges, etc.) No time limit for this item.			

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
		Time frame: past 36 mont	ths	
2	Grants or contracts from any entity (if not indicated in item #1 above).	None		
3	Royalties or licenses	None Non		
4	Consulting fees	None ■		
5	Payment or honoraria for lectures, presentations , speakers bureaus, manuscript writing or educational events	None None		
6	Payment for expert testimony	None		
7	Support for attending meetings and/or travel	None		

	Name all entities with whom you have this relationship or indicate none (add rows as needed) Specifications/Comments (expansion payments were made to you institution)		ts were made to you or to your	
8	Patents planned, issued or pending	⊠ None		
9	Participation on a Data Safety Monitoring Board or Advisory Board	Member of the NIHR Evidence Synthesis Programme Prioritisation and Advisory Gro (ESPPAG)		Since January 2023.
1 1 1	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options	None None None		
1 2	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None		
1 3	Other financial or non-financial interests	None		
, ,	Please place an "X" next to the following statement to indicate your agreement: I certify that I have answered every question and have not altered the wording of any of the questions on this form.			